Analysis of Adverse Drug Reactions in Pediatric Patients with Epilepsy: An Intensive Pharmacovigilance Study
Ernestina Hernández García,
Lizbeth Naranjo,
Luz Adriana Pichardo-Macías,
María Josefa Bernad Bernad,
Lucila Isabel Castro-Pastrana,
Matilde Ruíz García,
Tanya Alejandra García Bernal,
Jessica Lizbeth Mendoza Solís,
David Calderón Guzmán,
Luisa Díaz-García,
Julieta Griselda Mendoza-Torreblanca,
Juan Luis Chávez Pacheco
Affiliations
Ernestina Hernández García
Laboratorio de Farmacología, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico
Lizbeth Naranjo
Departamento de Matemáticas, Facultad de Ciencias, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico
Luz Adriana Pichardo-Macías
Departamento de Fisiología, Instituto Politécnico Nacional, Escuela Nacional de Ciencias Biológicas, Ciudad de Mexico 07738, Mexico
María Josefa Bernad Bernad
Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico
Lucila Isabel Castro-Pastrana
Departamento de Ciencias Químico Biológicas, Universidad de las Américas Puebla, Puebla 72810, Mexico
Matilde Ruíz García
Servicio de Neurología, Dirección Médica, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico
Tanya Alejandra García Bernal
Farmacia Intrahospitalaria, Hospital General Dr. Manuel Gea González, Ciudad de Mexico 14080, Mexico
Jessica Lizbeth Mendoza Solís
Facultad de Medicina, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04360, Mexico
David Calderón Guzmán
Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico
Luisa Díaz-García
Departamento de Metodología de la Investigación, Subdirección de Investigación Clínica, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico
Julieta Griselda Mendoza-Torreblanca
Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico
Juan Luis Chávez Pacheco
Laboratorio de Farmacología, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico
Epilepsy is a chronic neurological disease characterized by the presence of spontaneous seizures, with a higher incidence in the pediatric population. Anti-seizure medication (ASM) may produce adverse drug reactions (ADRs) with an elevated frequency and a high severity. Thus, the objective of the present study was to analyze, through intensive pharmacovigilance over 112 months, the ADRs produced by valproic acid (VPA), oxcarbazepine (OXC), phenytoin (PHT), and levetiracetam (LEV), among others, administered to monotherapy or polytherapy for Mexican hospitalized pediatric epilepsy patients. A total of 1034 patients were interviewed; 315 met the inclusion criteria, 211 patients presented ADRs, and 104 did not. A total of 548 ASM-ADRs were identified, and VPA, LEV, and PHT were the main culprit drugs. The most frequent ADRs were drowsiness, irritability, and thrombocytopenia, and the main systems affected were hematologic, nervous, and dermatologic. LEV and OXC caused more nonsevere ADRs, and PHT caused more severe ADRs. The risk analysis showed an association between belonging to the younger groups and polytherapy with ADR presence and between polytherapy and malnutrition with severe ADRs. In addition, most of the severe ADRs were preventable, and most of the nonsevere ADRs were nonpreventable.